PDE4 inhibitors - A review of the recent patent literature

IDrugs

Volumn 4, Issue 3, 2001, Pages 312-338

  Martin, Thomas J ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000501191     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Beavo J, Loughney K, Pruniaux MP, Souness J: PDE inhibitors: Drugs with an expanding range of therapeutic uses. William Harvey Research Conference (1999) 2(Nice):21;
2. Houslay M: PDE Inhibitors Second William Harvey Research Conference (Part II) Drugs with an Expanding Range of Therapeutic Uses, Nice, France. IDdb Meeting Report (1999);
3. Torphy TJ: PDE inhibitors: Drugs with an expanding range of therapeutic uses. IDrugs (2000) 3(2):170-173. NeW information about PDE subtypes, asthma, rheumatoid arthritis, SB207499, toxicityof RP-73401 and strategies to improve piclamilast.
4. Beavo JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. PhysiolHev(1995) 75:725-748.
5. Beavo JA, Reifsnyder DH: Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol Sei (1990) 11:150-155.
6. Torphy TJ: Phosphodiesterase isoenzymes. Am J Respir Crit Care Med(1998) 157:351-370.
7. Bames PJ: Therapeutic strategies for allergic diseases. Nature (1999) 402(6760 Suppl):B31-38. An excellent review of current therapies for atopic diseases, including new anti-inflammatory and specific anti-allergic drugs and the possibilities for preventative and even curative treatments.
8. Mueller T, Engels P, Fozard JR: Subtypes of the type 4 CAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol Sei(1996) 17:294-298. A very interesting biological characterization of the four PDE4 subtypes (PDE4A-D), including high-affinity rolipram binding and a table of expression patterns ofmRNAs for human PDE4 isogenes.
9. Ashton MJ, Cook DC, Fluton G, Kartsson J-A, Palfreyman UN, Raebum D, Ratcliffe AJ, Souness JE, Thuraivatnam S, Vicker N: Selective type IV phosphodiesterase Inhibitors as antiasthmatic agents. J Med Chem (1994) 37:1696-1703.
10. Chan S, Hanifin JM: Differential inhibitor effects on phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med(1993) 121:44-51.
11. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG: Phosphodiesterase (PDE)4 inhibitors: anti-Inflammatory drugs of the future? Trends Pharmacol Sei(W97) 18:164-171. An excellent review of the effects of PDE4 inhibitors on models of inflammatory diseases in vivo.
12. Torphy TJ: Action of mediators on airway smooth muscle functional antagonism as a mechanism for bronchodilator drugs. Agents Actions (1998) 23(Suppl):S37-53.
13. Souness JE, Foster M: Potential of phosphodiesterase type IV inhibitors in treatment of rheumatoid arthritis. IDrugs (1998) 1(5):541-553.
14. Palfreyman MN: Phosphodiesterase typo IV inhibitors as antiinflammatory agents. Drugs Future (1995) 20(8):793-804. An overview of promising selective PDE4 inhibitors and analogs, including structure-activity relationships, syntheses, therapeutic'potential in asthma and other inflammatory diseases.
15. Rolipram. IDdb Drug Report (2000), and references therein.
16. Meiji Seika's R&D pipeline. Pharma Japan (1997) 1534:3.
17. Landells L, Jensen M, Orr L, Spina D, Souness J, O'Connor B, Page C: Effects of PDE3 and PDE4 Inhibitors on proliferation of human peripheral blood mononuclear cells from healthy and asthmatic donors. Br J Pharmacol (W99) 126(Suppl):Abs 163P.
18. Bivalacqua TJ, Champion HC, Rajasekeran M, Sikka SC. Kadowitz PJ, Dohcrty PC, Hellstrom WJ: Potentiation of erectile responses and cAMP accumulation by combination of prostaglandine E-1 and rolipram, a selective Inhibitor of the type 4 phosphodiesterase (PDE4). JUrol(1999) 162(5):1848.
19. Schering AG: IDdb Company Communication (2000) August 08.
20. Byk Gulden: Roflumilast. Company World Wide Web Site (1999).
21. PDE4 inhibitors 1999. Exp Opin TTier Par (1999) 9:1101-1118.
22. Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W: Safety and efficacy of the new PDE4 inhibitor roflumitast, administered to patients with exercise-induced asthma over 4 weeks. Am J Resp Crit Care Med (2000) 161 (3 Part 2):A505. Data from a double-blind, randomized, crossover trial in 16 patients with exercise-induced asthma.
23. Souness JE: Potential unfulfilled - RP 73401 and beyond: ACS (1999) 217(Anaheim):MEDI 268. Preclinical toxicological data in rats were disclosed.
24. Agathangelou P: Viral proteases and phosphodiesterase inhibitors. IDrugs (1999) 2(6):523-525.
25. Torphy TJ: Phosphodiesterase 4 inhibitors for the treatment of pulmonary diseases: From concept to clinic. Mediators Inflamm (1999) 8(Suppl 1):AbstS-04-1.
26. Compton CH, Gubb J, Cedar E, Nieman RB, Amit O, Brambilla C, Ayres J: The efficiacy of Ariflo (SB 207499), a second generation, oral PDE4 inhibitor, in patients with COPD. Am J Respir Crit Care Med (1999)159:A806. Clinical data from a randomized, placebo-controlled phase II study with 424 patients.
27. Nieman RB, Fisher BD, Amit O, Dockhom RJ: SB 207499 (Ariflo), a second generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma. Am J Resp Crit Care Merf(1998) 157:413.
28. Aimirall: Drug development pipeline: LAS-30538, LAS-30563, LAS30813, LAS30989, LAS-31180, LAS-31270, LAS-31334, LAS-31396, LAS-31727, arofyliine and almotriptan. Company Communication (1996).
29. Newbold P, Mather M, Young A: Effect of phosphodiesterase (PDE) inhibitors on active antigen-induced skin inflammation in sensitised guinea-pigs. Eur Respir J(1998) 12(Suppl 29):P538.
30. Souness J: PDE Inhibitors - Second William Harvey Research Conference Drugs with an expanding range of therapeutic uses. Nice, France. IDdb Meeting Report (1999).
31. Pruniaux M-P, Rocher M-N: The novel phosphodiesterase 4 inhibitor CI-1018 inhibits antigen-induced lung eosinophilia in sensitized Brown-Norway rats - Comparison with rolipram. Mediators Inflamm (1999) 8(Suppl 1):Abs S-04-6.
32. Merck/Celltech collaboration on PDE Type IV inhibitors. News Release (1996).
33. Ferienga P, Biasini J, Mardini F, Semeraro C, Fehlmann M: Differential ability of PDE4 inhibitors preventing antigen-induced broncho-spasm in guinea-pigs. J Allergy Clin Immunol(1999) 103(1 Part 2):Abs 485.
34. Jones TR, McAulitfe M, McFartane CS, Piechuta H, McDonald D, Rodger IW: Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma. Can JPhysiolPharmacolC(99&) 76(2):760.
35. Harbinson PL, MacLeod D, Hawksworth R, OToole S, Sullivan PJ, Heath P, Kilfeather S, Page CP, Costello, Holgate ST, Lee TH: The effect of a novel active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J(1997) 10:1008-1014.
36. Montana J, Cooper N, Dyke H, Oxford J, Gristwood R, Löwe C, Kendall H, Buckley G, Maxey R, Wameck J, Gregory J, Gowers L, Galleway F, Wills R, Naylor R, Tudhalar B, Broadley K, Danahay H: Activity of D4418, a novel phosphodiesterase 4 (PDE4) inhibitor, effects in cellular and animal models of asthma and early clinical studies. Am J Respir Crit Care Med (1999) 159(3 Part 2):A624.
37. Celltech Chiroscience pic : Celttech merger with Medeva completed creating one of the largest European biopharmaceutical companies with substantial US operations. News Release (2000).
38. Chiroscience Group pic: Chiroscience R&D announces key milestone in PDE4 collaboration with Schering-Plough. News Release (1999).
39. Celgene Corp: Immunotherapeutics program - Celgene Corp. Company World Wide Web Site (2000).
40. 3d. Celgene Corp: Celgene Corporation announces major progress for development of SelCID class of compounds, including clinical safety data IND for evaluation in Crohn's disease treatment to be submitted in 4Q1998. News Release (1998).
41. American Home Products Corp: Annual Report - American Home Products -1994. Annual Report ( 1994).
42. Heaslip RJ, Evans DY, Sickels BD: Pulmonary selectivity of WAYPDA-641 and references POE-IV inhibitors in the dog. FASEB J (1994) 8(4 Part 1):Abs 2146.
43. Glaser KB, Hulkower Kl, Cartson RP: Therapeutic approaches to allergic and inflammatory diseases: Fourth Annual Midwest Meeting of the Inflammation Research Association. Inflamm Res (1996)45:438-441.
44. Wright KF et at Differential in vivo and in vitro bronchorelaxant activities of CP-80633, a selective phosphodiesterase 4 inhibitor. Can J Physiol Pharmacol (1997) 75(8):1001.
45. Cohan VL, Showell HJ, Fisher DA, Pazoles CJ, Watson JW, Turner CR, Cheng J: In vitro pharmacology of a novel adenosine 3'-5'-cyclic monophosphate-specific phosphodiesterase (PDE) type 4 inhibitor. J Pharmacol Exp Tfcer(1996) 278:1356-1361.
46. Schwertschlag US, Cerimele BJ, McNay JL, Bowsher RR, Rowe H: Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels. Pharmacology (1993) 46(3):142-145.
47. Tibenelast Drug Date flep(1990)12(6):467.
48. Wright CD, Devall U, Aker KA, Thueson DO, Conroy MC: Differential regulation of human. eosinophil, macrophage, and neutrophil functions by the allergic mediator release inhibitor CI-959. Agents Actions(1992) 36(1-2):11-16.
49. Hisamichi H, Takayama K, Iwata M, Kubota H, Kawano N, Aoki M, Isomura Y: Synthetic studies on selective type IV phosphodiesterase (PDE IV) inhibitors. ACS (1998) 215 (Dallas):MEDI 049.
50. Takayama K, Iwata M, Okamoto Y, Aoki M, Niwa A, Isomura Y: Synthetic studies on selective type IV phosphodiesterase (PDE IV) inhibitors. ACS Meeting (1997) 214 (San Francisco):MEDI 245.
51. Hisamichi H, Takayama K, Iwata M, Kubota H, Kawano N, Aoki M, Isomura Y: Synthetic studies on selective type IV phosphodiesterase (PDE IV) inhibitors. II. ACS (1996) 215(Dallas):MEDI 049.
52. Fitch N, Freeman MS, Sturton RG, Harris P, Lindell D, Gundel R: The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models. Am J Respir Crit Care Med (2000) 161(3 Part2):A201.
53. Fitzgerald MF, Briggs BA, Thompson AM, Edwards DF, Sturton RG: The evaluation of a selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models. Am J Respir Crit Care Med (2000) 161 (3 Part 2):A201.
54. Landells U, Jensen MW, Spina D, Gale DD, Miller AJ, Nichols T, Smith K, Rotshteyn Y, Burch RM, Page CP, O'Connor BJ: Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294A inhibits ex vivo agonist-induced cell activation. Eur Respir J (1998) 12(Suppl 28):Abs P2393.
55. Norman P: Conquering Airway Inflammation in the 21 st Century. National Heart and Lung Institute, London, UK. IDdbAfeeftng Report (1997).
56. Gale DD, Landells LJ, Spina D, Miller AJ, Smith K, Nichols T, Rotshteyn Y, Tonelli F, Lacouture P, Burch RM, Page CP, O'Connor BJ: Pharmacodynamic-pharmacokinetic (PD/PK) profile of the phosphodiesterase (PDE)4 inhibitor V11294A, in human volunteers. Am J Respir Crit Care Med(1999) 159(3 Part2):A108.
57. Nicholson CD, Shahid M, Bruin J, Barron E, Spiers J, de Boer J, van Amsterdam RGM, Zaagsma J, Kelly JJ et at Characterization of OHG 20241, a combined phosphodiesterase 1V/III cyclic nucleotide phoshodiesterase inhibitor for asthma. J Pharmacol Exp 77>er(1995) 274:678-687.
58. Nicholson C-D, Shahid M, Bruin J, De Boer J, Van Amsterdam RGM, Zaagsma J, Dent G, Glembycz M-A, Bames P-J: Org 20241, a cyclic nucleotide phosphodiesterase Inhibitor for asthma. Br J Pharmacol (1991)104:15P.
59. Santing RE, Rohof AAB, van der Zee NM, Zaagsma J: Effect of subtype selective phosphodiesterase inhibitors on allergeninduced airway obstruction, hyperreactivity and inflammation in sensitized guinea pigs. Am J Respir Crit Care Med (1996) 153(4 Part 2):A347.
60. Leo Pharmaceutical Products Ltd: Drug development pipeline: tinzaparin, GS-1590, EB-1089, CHS-828, P-1075, EO-1428, HEP-688, HEP-689, SB-235699. Company Communication (1999).
61. Kaplan JM, Herzyk DJ, Ruggieri EV, O'Leary Bartus J, Esser KM, Bugelski PJ: Effect of TNF alpha production inhibitors BRL-61063 and pentoxifyliine on the response of rats to poly I:C. Toxicology (1995)95:187-196.
62. Jensen L, Griswold DE, Aaes H, Skak-Nielsen T, Hansen JR, Bramm E, Binderup L: Cipamfylline - a promising drug for topical treatment of atopic dermatitis. Mediators Inflamm (1999) 8(Suppl 1):AbsP-11-10.
63. Everitt DE, Boike S, Davies B, Zaritfa N, Audet P, Brown L Pharmacokinetics, tolerability and TNF-alpha inhibitory activity of 1,3-dKcyclopropyl-methyl)-8-aminoxanthine (BRL-61063). Annu Meet Am Soc Clin Pharmacol (1994):P1108.
64. Marx D, Röllig H, Szelenyi I: Inhibition of allergen induced bronchial hyperreactivity (HBR) in BP-2 mice by cyclosporine A, fluticasone and selective PDE4-inhibitors. J Allergy Clin Immunol (1998) 101(1 Part 2):Abs 42...
65. Bishop P: Medicinal Chemistry XVth EFMC International Symposium (Part V); Poster Highlights, Edinburgh, Scotland, UK. IDdb Meeting Report (1998).
66. Marx D, Szelenyi I: The In vivo activity of AWD-12-281, a potent inhibitor for the treatment of allergic asthma. J Allergy Clin Immunol (1999)103(1 Part 2):Abs 484.
67. Poppe H, Küsters S, Szelenyi I: Comparison of a new selective PDE4-inhibitor AWD 12-281 with budesonide on lymphocyte entry and eosinophilia in the bronchoalveolar space of the Brown Norway rat. Am J Respir Crit Care Med (2000) 161 (3 Part 2):A184.
68. Szelenyi I, Marx D, Poppe H: The in vivo activity of AWD-12281, a potent PDE4 inhibitor for the treatment of allergic asthma. J Allergy Clin Immunol(1999) 103(1 ):Abs 484.
69. McGarry DG, Regan JR, Volz FA, Hulme C, Moriarty KJ, Djuric SW, Sôuness JE, Miller BE, Sweeney DM: Benzofuran based PDE4 inhibitors. Bioorg Med Chem (1999) 7:1131-1139.
70. Pascal Y, Andrianjara CR, Auclair E, Avenel N, Bertin B, Calvet A, F'eru F, Lardon S, Moodley I, Ouagued M, Payne A, Pruniaux MP, Szilagyi C: Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-W]indoles: Novel PDE4 inhibitors. Bioorg Med Chem Lett (2000) 10:35-38.
71. Groneberg RD, Bums CJ, Morrissette MM, Darnbrough S, Djuric SW, Condon SM, McGreehan GM, Labaudiniere R, Neuenschwander K, Scotese AC, Kline JA: Dual Inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template. J Med Chem (1999) 42:541-544. Describes the first compounds (and syntheses thereof) that simultaneously inhibit both PDE4 and MMPs 1,2 and 3.